Parallel Advisors, LLC Cti Biopharma Corp Transaction History

Parallel Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 20, 2024	BUY	$4.2 - $6.01 $491 - $703	117 New	117 $0
Q1 2023 Apr 25, 2023	BUY	$4.2 - $6.01 $352 - $504	84 Added 254.55%	117 $0
Q4 2022 Feb 03, 2023	BUY	$4.45 - $6.17 $146 - $203	33 New	33 $0
Q2 2022 Aug 01, 2022	BUY	$3.55 - $6.27 $102 - $181	29 New	29 $0

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.